We are live on ! Find out more
PAI

ProQuest Associates IV Portfolio holdings

AUM $53M
1-Year Est. Return 3.35%
This Fund
S&P 500
This Quarter Est. Return
+18.91%
1 Year Est. Return
+3.35%
3 Year Est. Return
+113.14%
5 Year Est. Return
10 Year Est. Return
AUM
$87M
AUM Growth
+$11.7M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
5
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
URGN icon
1
UroGen Pharma
URGN
$2.13B
$54.5M 62.61%
1,096,024
MRSN
2
DELISTED
Mersana Therapeutics
MRSN
$15.1M 17.33%
38,228
AGRX
3
DELISTED
Agile Therapeutics
AGRX
$13M 14.96%
2,531
IMDZ
4
DELISTED
Immune Design Corp.
IMDZ
$4.08M 4.69%
1,236,394
EGRX
5
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$357K 0.41%
6,777

Similar funds

ProQuest Associates IV's Q1 2018 Portfolio in Review

As of Q1 2018, ProQuest Associates IV held 5 positions worth $87M, up 16% from $75.3M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2018: portfolio turnover was 0%. ProQuest Associates IV opened no new positions and made no exits, leaving the 5-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • ProQuest Associates IV's ten largest holdings make up 100% of its $87M portfolio in Q1 2018.
  • ProQuest Associates IV opened 0 new positions and closed 0 in Q1 2018.
  • ProQuest Associates IV's portfolio value rose 16% quarter-over-quarter to $87M.

Based on ProQuest Associates IV's 13F filing for Q1 2018, filed 15 May 2018.